BIIB · Biogen Inc.
$209.83
-0.82 (-0.39%)
At close · Aug 14
Market Cap
$30.98B
Shares
147.64M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Christopher Viehbacher | President and Chief Executive Officer | $23,646,004 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer | $8,132,517 |
| Nicole C. Murphy | Head of Pharmaceutical Operations and Technology | $7,575,505 |
| Priya Singhal | Head of Development | $7,571,387 |
| Robin Kramer | Executive Vice President and Chief Financial Officer | $5,806,584 |
| Michael McDonnell | Former Executive Vice President and Chief Financial Officer | $270,850 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher Viehbacher | President and CEO | $24,166,665 |
| Michael McDonnell | Executive Vice President, Chief Financial Officer | $6,826,734 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer | $6,505,829 |
| Priya Singhal | Head of Development | $6,387,663 |
| Nicole C. Murphy | Head of Pharmaceutical Operations and Technology | $5,740,359 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael McDonnell | Executive Vice President, Chief Financial Officer | $7,167,601 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer | $6,703,852 |
| Nicole C. Murphy | Head of Pharmaceutical Operations and Technology | $5,714,319 |
| Rachid Izzar | Head of Global Product Strategy & Commercialization | $5,447,830 |
| Christopher Viehbacher | President and CEO | $4,069,913 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Christopher Viehbacher | President and CEO | $30,488,593 |
| Michel Vounatsos | Former Chief Executive Officer | $26,625,221 |
| Michael McDonnell | Executive Vice President, Chief Financial Officer | $7,209,834 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer | $6,790,152 |
| Chirfi Guindo | Former Executive Vice President, Global Product Strategy and Commercialization | $5,382,348 |
| Ginger Gregory | Executive Vice President, Chief Human Resources Officer | $5,080,258 |
| Nicole C. Murphy | Head of Pharmaceutical Operations and Technology | $4,929,712 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michel Vounatsos | Former Chief Executive Officer | $17,689,665 |
| Michael McDonnell | Executive Vice President and Chief Financial Officer | $5,918,371 |
| Chirfi Guindo | Former Executive Vice President, Global Product Strategy and Commercialization | $5,750,662 |
| Alfred Sandrock | Former Executive Vice President, Research & Development | $5,737,900 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer | $5,639,306 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michel Vounatsos | Former Chief Executive Officer | $18,659,829 |
| Jeffrey Capello | Former Executive Vice President and Chief Financial Officer | $9,221,511 |
| Michael McDonnell | Executive Vice President and Chief Financial Officer | $6,575,557 |
| Alfred Sandrock | Executive Vice President, Research & Development | $6,226,969 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer and Secretary | $5,470,045 |
| Chirfi Guindo | Former Executive Vice President, Global Product Strategy and Commercialization | $5,132,795 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michel Vounatsos | Chief Executive Officer | $18,159,858 |
| Jeffrey Capello | Former Executive Vice President and Chief Financial Officer | $5,814,089 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer And Secretary | $5,455,010 |
| Alfred Sandrock | Executive Vice President, Research & Development | $5,312,565 |
| Michael D.Ehlers | Former Executive Vice President Research & Development | $5,287,984 |
| Global Product Strategy | And Commercialization | $4,694,522 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michel Vounatsos | Chief Executive Officer | $16,168,646 |
| Michael D.Ehlers | Former Executive Vice President Research & Development | $7,046,651 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer And Secretary ChirfiGuindo | $6,353,784 |
| Jeffrey Capello | Former Executive Vice President and Chief Financial Officer | $4,476,719 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Michael D.Ehlers | Former Executive Vice President Research & Development | $5,064,981 |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer and Secretary | $5,061,242 |
| Jeffrey Capello | Executive Vice President and Chief Financial Officer | $548,978 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robin Kramer | Chief Financial Officer | Appointed | 2025-01-15 |
| Michael McDonnell | Chief Financial Officer | Retired | 2025-01-15 |
| Sean Godbout | Vice President, Chief Accounting Officer & Global Corporate Controller | Appointed | 2025-01-15 |
| Robin Kramer | Chief Financial Officer | Appointed | 2024-10-30 |
| Michael McDonnell | Chief Financial Officer | Retired | 2024-10-30 |
| Sir Menelas (Mene) Pangalos, Ph.D. | director | Appointed | 2024-09-12 |
| Lloyd B. Minor, M.D. | director | Appointed | 2024-09-12 |
| Monish Patolawala | director | Appointed | 2023-11-08 |
| Caroline D. Dorsa | Chair of the Board | Appointed | 2023-03-09 |
| Christopher A. Viehbacher | director | Appointed | 2022-11-10 |
| Christopher A. Viehbacher | President and CEO | Appointed | 2022-11-10 |
Key facts
CIK
875045
CUSIP
09062X103
13F (30d)
947 filings
910 filers
Visit website
Investor relations